These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31732918)

  • 41. Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting.
    Thukkani AK; Agrawal K; Prince L; Smoot KJ; Dufour AB; Cho K; Gagnon DR; Sokolovskaya G; Ly S; Temiyasathit S; Faxon DP; Gaziano JM; Kinlay S
    J Am Coll Cardiol; 2015 Sep; 66(10):1091-101. PubMed ID: 26337986
    [TBL] [Abstract][Full Text] [Related]  

  • 42. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry).
    Shah B; Baber U; Pocock SJ; Krucoff MW; Ariti C; Gibson CM; Steg PG; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Iakovou I; Dangas G; Aquino MB; Sartori S; Chieffo A; Moliterno DJ; Colombo A; Mehran R
    Circ Cardiovasc Interv; 2017 Sep; 10(9):. PubMed ID: 28916600
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence and clinical impact of high platelet reactivity in patients with chronic kidney disease treated with percutaneous coronary intervention: An updated systematic review and meta-analysis.
    Mangiacapra F; Paolucci L; Viscusi MM; Mangiacapra R; Ferraro PM; Nusca A; Melfi R; De Luca L; Gabrielli D; Ussia GP; Grigioni F
    Catheter Cardiovasc Interv; 2022 Mar; 99(4):1086-1094. PubMed ID: 35088526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. On-Treatment Platelet Reactivity and Ischemic Outcomes in Patients With Diabetes Mellitus: Two-Year Results From ADAPT-DES.
    Shahim B; Redfors B; Stuckey TD; Liu M; Zhou Z; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Srdanovic I; Madhavan MV; Mazzaferri EL; Mehran R; Ben-Yehuda O; Kirtane AJ; Stone GW
    J Am Heart Assoc; 2023 Jan; 12(1):e026482. PubMed ID: 36565189
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
    Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
    Maeng M; Steg PG; Bhatt DL; Hohnloser SH; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Ten Berg JM; Cannon CP;
    JACC Cardiovasc Interv; 2019 Dec; 12(23):2346-2355. PubMed ID: 31806216
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sex Differences in Midterm Prognostic Implications of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents in East Asian Patients: Results From the PTRG-DES (Platelet Function and Genotype-Related Long-Term Prognosis in Drug-Eluting Stent-Treated Patients With Coronary Artery Disease) Consortium.
    Kim SJ; Her AY; Jeong YH; Kim BK; Joo HJ; Park Y; Chang K; Song YB; Ahn SG; Suh JW; Lee SY; Cho JR; Kim HS; Kim MH; Lim DS; Shin ES;
    J Am Heart Assoc; 2023 May; 12(9):e027804. PubMed ID: 37119080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
    Christ G; Siller-Matula JM; Francesconi M; Dechant C; Grohs K; Podczeck-Schweighofer A
    BMJ Open; 2014 Oct; 4(10):e005781. PubMed ID: 25361837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.
    Redfors B; Généreux P; Witzenbichler B; Maehara A; Weisz G; McAndrew T; Mehran R; Kirtane AJ; Stone GW
    Am Heart J; 2018 Mar; 197():142-149. PubMed ID: 29447774
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.
    Kheiri B; Osman M; Abdalla A; Haykal T; Pandrangi PV; Chahine A; Ahmed S; Osman K; Bachuwa G; Hassan M; Bhatt DL
    Catheter Cardiovasc Interv; 2019 Jun; 93(7):1246-1252. PubMed ID: 30403317
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.
    El Ghannudi S; Ohlmann P; Jesel L; Radulescu B; El Adraa E; Crimizade U; Wiesel ML; Gachet C; Morel O
    Atherosclerosis; 2011 Aug; 217(2):465-72. PubMed ID: 21524751
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multicenter research of bleeding risk between prasugrel and clopidogrel in Japanese patients with coronary artery disease undergoing percutaneous coronary intervention.
    Tokimasa S; Kitahara H; Nakayama T; Fujimoto Y; Shiba T; Shikama N; Nameki M; Himi T; Fukushima KI; Kobayashi Y
    Heart Vessels; 2019 Oct; 34(10):1581-1588. PubMed ID: 30944971
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass.
    Youn YN; Yi G; Lee S; Joo HC; Yoo KJ
    Am Heart J; 2014 Jun; 167(6):818-25. PubMed ID: 24890530
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention.
    Wang HY; Dou KF; Yin D; Xu B; Zhang D; Gao RL
    Am J Cardiol; 2020 Oct; 133():61-70. PubMed ID: 32811654
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized Comparison of Intensified and Standard P2Y
    Mehilli J; Baquet M; Hochholzer W; Mayer K; Tesche C; Aradi D; Xu Y; Thienel M; Gschwendtner S; Zadrozny M; Jochheim D; Sibbing D; Schüpke S; Mansmann U; Hoffmann E; Kastrati A; Neumann FJ; Massberg S
    Circ Cardiovasc Interv; 2020 Jun; 13(6):e008649. PubMed ID: 32527192
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry.
    Sorrentino S; Sartori S; Baber U; Claessen BE; Giustino G; Chandrasekhar J; Chandiramani R; Cohen DJ; Henry TD; Guedeney P; Ariti C; Dangas G; Gibson CM; Krucoff MW; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Urban P; Mehran R
    Circ Cardiovasc Interv; 2020 Apr; 13(4):e008226. PubMed ID: 32216472
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
    Cassese S; De Luca G; Villari B; Berti S; Bellone P; Alfieri A; Montinaro A; Quaranta G; Marraccini P; Piscione F;
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):408-16. PubMed ID: 21735531
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).
    Droppa M; Tschernow D; Müller KA; Tavlaki E; Karathanos A; Stimpfle F; Schaeffeler E; Schwab M; Tolios A; Siller-Matula JM; Gawaz M; Geisler T
    PLoS One; 2015; 10(3):e0121620. PubMed ID: 25799149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J
    BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation.
    Généreux P; Giustino G; Redfors B; Palmerini T; Witzenbichler B; Weisz G; Stuckey TD; Maehara A; Mehran R; Kirtane AJ; Stone GW
    Int J Cardiol; 2018 Oct; 268():61-67. PubMed ID: 30041804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.